Membrane type 1-matrix metalloproteinase promotes human prostate cancer invasion and metastasis

Summary

Development of metastases requires cancer cells to breach underlying basement membrane, migrate through interstitial stroma and gain access to blood or lymphatic vessels. Membrane type 1-matrix metalloproteinase (MT1-MMP) has been linked with these processes. Expression of MT1-MMP in human prostate cancer correlates with the stage of this disseminated disease. The mechanism underlying this observation, however, still remains to be understood. To study the role of MT1-MMP in prostate cancer dissemination, endogenous and recombinant MT1-MMP expressed in human prostate cancer cell lines (DU-145 and LNCaP) were examined. Using FITC-labeled Ma-trigel, a soluble basement membrane extract coated coverslips, LNCaP cells stably expressing a chimera of MT1-MMP and Green Fluorescent Protein (MT1-GFP) degraded Matrigel and readily migrated over degraded substrates. The degradation of Matrigel by LNCaP cells expressing MT1-GFP was sensitive to MMP inhibitors, CT-1746 and TIMP-2, but not TIMP-1. Cell migration was dramatically enhanced by expression of MT1-MMP. By employing surgical orthotopic implantation of LNCaP cells stably expressing MT1-GFP into the prostate gland of immunodeficient mice, we demonstrated that MT1-MMP promotes lymph node and lung metastasis of prostate cancer cells. Together, these results emphasize the pivotal role of MT1-MMP in prostate cancer dissemination and confirm that MT1-MMP is a suitable target to prevent cancer metastasis.

Keywords

MT1-MMP - cell migration - invasion - metastasis - prostate cancer

• References

• 1 American Cancer Society. Estimated New Cancer Cases and Deaths by Sex for All Sites. Cancer Facts and Figures 2004. http://www.cancer.org/downloads/STT/CAFF_finalPWSecured.pdf .
• 2 Ross JS, Jennings TA, Nazeer T. et al. Prognostic factors in prostate cancer. Am J Clin Pathol 2003; 120 (Suppl. 01) S85-100.
• 3 Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996; 49: 117-37.
• 4 Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
• 5 Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2001; 19: 6642-50.
• 6 Udayakumar TS, Chen ML, Bair EL. et al. Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration. Cancer Res 2003; 63: 2292-9.
• 7 Gilles C, Polette M, Seiki M. et al. Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase- 2 activation in the metastatic progression of breast carcinoma. Lab Invest 1997; 76: 651-60.
• 8 Davies B, Miles DW, Happerfield LC. et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993; 67: 1126-31.
• 9 Itoh Y, Takamura A, Ito N. et al. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumour cell invasion. EMBO J 2001; 20: 4782-93.
• 10 Cao J, Kozarekar P, Pavlaki M. et al. Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration. J Biol Chem 2004; 279: 14129-39.
• 11 Noel A, Gilles C, Bajou K. et al. Emerging roles for proteinases in cancer. Invasion Metastasis 1997; 17: 221-239
• 12 Yurchenco PD, Smirnov S, Mathus T. Analysis of basement membrane self-assembly and cellular interactions with native and recombinant glycoproteins. Methods Cell Biol 2002; 69: 111-44.
• 13 Orkin RW, Gehron P, McGoodwin EB. et al. A murine tumour producing a matrix of basement membrane. J Exp Med 1997; 145: 204-20.
• 14 Kleinman HK, McGarvey ML, Liotta LA. et al. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 1982; 21: 6188-93.
• 15 Price JT, Bonovich MT, Kohn EC. The biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol 1997; 32: 175-253.
• 16 Duffy MJ. The biochemistry of metastasis. Adv Clin Chem 1996; 32: 135-66.
• 17 Ohuchi E, Imai K, Fujii Y. et al. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997; 272: 2446-51.
• 18 Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumour invasion. Cancer Lett 2003; 194: 1-11.
• 19 Banyard J, Zetter BR. The role of cell motility in prostate cancer. Cancer Metastasis Rev 1998; 17: 449-58.
• 20 Liao X, Thrasher JB, Pelling J. et al. Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 2003; 144: 1656-63.
• 21 Nagakawa O, Murakami K, Yamaura T. et al. Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett 2000; 155: 173-9.
• 22 Jung M, Romer A, Keyszer G. et al. mRNA expression of the five membrane-type matrix metalloproteinases MT1-MT5 in human prostatic cell lines and their down-regulation in human malignant prostatic tissue. Prostate 2003; 55: 89-98.
• 23 Upadhyay J, Shekarriz B, Nemeth JA. et al. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with highgrade prostatic intraepithelial neoplasia. Clin Cancer Res 1999; 5: 4105-10.
• 24 Cao J, Drews M, Lee HM. et al. The propeptide domain of membrane type I matrix metalloproteinase is required for binding of tissue inhibitor of metalloproteinases and for activation of pro-gelatinase A. J Biol Chem 1998; 273: 34745-52.
• 25 Chen WT, Yeh YY, Nakahara H. An in vitro cell invasion assay: determination of cell surface proteolytic activity that degrades extracellular matrix. J Tissue Cult Methods 1994; 16: 177-81.
• 26 Albrecht-Buehler G. The phagokinetic tracks of 3T3 cells. Cell 1997; 11: 395-404.
• 27 Rembrink K, Romijn JC, van der Kwast TH. et al. Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate 1997; 31: 168-74.
• 28 Zucker S, Hymowitz M, Rollo EE. et al. Tumourigenic potential of extracellular matrix metalloproteinase inducer (EMMPRIN)). Am J Pathol 2001; 158: 1921-8.
• 29 Zhang X, Kon T, Wang H. et al. Enhancement of hypoxia- induced tumour cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res 2004; 64: 8139-42.
• 30 Hotary K, Allen E, Punturieri A. et al. Regulation of cell invasion and morphogenesis in a threedimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol 2000; 149: 1309-23.
• 31 Udayakumar TS, Nagle RB, Bowden GT. Fibroblast growth factor-1 transcriptionally induces membrane type-1 matrix metalloproteinase expression in prostate carcinoma cell line. Prostate 2004; 58: 66-75.
• 32 Webber MM, Bello D, Quader S. Immortalized and tumourigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications. Prostate 1997; 30: 136-42.
• 33 Zucker S, Hymowitz M, Conner CE. et al. Rapid trafficking of membrane type 1-matrix metalloproteinase to the cell surface regulates progelatinase a activation. Lab Invest 2002; 82: 1673-84.
• 34 Overall CM, Sodek J. Concanavalin A produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases. J Biol Chem 2002; 265: 21141-51.
• 35 Lee MH, Rapti M, Murphy G. Unveiling the surface epitopes that render tissue inhibitor of metalloproteinase- 1 inactive against membrane type 1-matrix metalloproteinase. J Biol Chem 2003; 278: 40224-30.
• 36 Yang M, Jiang P, Sun FX. et al. A fluorescent orthotopic bone metastasis model of human prostate cancer. Cancer Res 1999; 59: 781-6.
• 37 Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003; 22: 177-203.
• 38 Patel BJ, Pantuck AJ, Zisman A. et al. CL1-GFP: an androgen independent metastatic tumour model for prostate cancer. J Urol 2000; 164: 1420-5.
• 39 Viallet PM, Vo-Dinh T. Monitoring intracellular proteins using fluorescence techniques: from protein synthesis and localization to activity. Curr Protein Pept Sci 2003; 4: 375-88.
• 40 Hayes N, Howard-Cofield E, Gullick W. Green fluorescent protein as a tool to study epidermal growth factor receptor function. Cancer Lett 2004; 206: 129-35.
• 41 Galvez BG, Matias-Roman S, Yanez-Mo M. et al. ECM regulates MT1-MMP localization with beta1 or alphavbeta3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells. J Cell Biol 2002; 159: 509-21.
• 42 Bartolome RA, Galvez BG, Longo N. et al. Stromal cell-derived factor-1alpha promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res 2004; 64: 2534-43.
• 43 Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 1989; 1: 571-3.
• 44 Fu X, Herrera H, Hoffman RM. Orthotopic growth and metastasis of human prostate carcinoma in nude mice after transplantation of histologically intact tissue. Int J Cancer 1992; 52: 987-90.
• 45 Pettaway CA, Pathak S, Greene G. et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996; 2: 1627-36.
• 46 Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003; 3: 422-33.
• 47 Koshikawa N, Giannelli G, Cirulli V. et al. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 2000; 148: 615-24.
• 48 Deryugina I E, Ratnikov I B, Postnova I T. et al. Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J Biol Chem 2002; 277: 9749-56.
• 49 Hamasuna R, Kataoka H, Moriyama T. et al. Regulation of matrix metalloproteinase-2 (MMP-2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP-2 expression and activation accompanying up-regulation of membrane type-1 MMP. Int J Cancer 1999; 82: 274-81.